Skip to main content
HCPCS Q5106 · Level II · Part B drug

Q5106: epoetin alfa-epbx (Retacrit), non-ESRD, HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q5106

Billing unit
1000 UNITS
Inj retacrit non-esrd use
ASP payment limit
$8.171
October 2026; +2.6% vs July 2026
Practitioner MUE
60
MAI 3
OPPS status
SI K
APC 9097
NCCI exposure
no PTP pairs
Coverage articles
4
15 states

TL;DR

HCPCS Q5106 is the Level II code for Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units, billed per 1000 UNITS. The Medicare Part B ASP payment limit for October 2026 is $8.171 per billing unit, up 2.6% from July 2026. The practitioner MUE allows up to 60 units per date of service (MAI 3), so a full 60-unit day is $490.26 at the current limit. Under OPPS it carries status indicator K in APC 9097. The descriptor restricts this code to non-ESRD use; the ESRD-on-dialysis counterpart is a separate code and billing the wrong one is a frequent reason for CARC 16 returns. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. Other HCPCS codes whose descriptor names epoetin alfa: Q5105 (for ESRD patients on dialysis; billed per 100 units); Q4081 (for ESRD patients on dialysis; non-biosimilar epoetin alfa; billed per 100 units); J0885 (non-biosimilar epoetin alfa). The ASP crosswalk maps 12 NDCs to it, sold as Retacrit by Pfizer Inc, Vifor (International) Inc. 4 Medicare coverage articles list the code across 15 states, including A56462.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q5106 at $8.171 per 1000 UNITS for October 2026, derived from manufacturer average sales price plus 6%, compared with $7.968 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q5106
QuarterPayment limitPerCoinsurance
October 2026$8.1711000 UNITS20%
July 2026$7.9681000 UNITS—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 12 NDCs from 2 labelers to Q5106. Report the NDC in the claim's drug segment and bill the number of Q5106 units that equals the quantity administered divided by 1000 UNITS; the last column gives units per full package.

NDCs that crosswalk to Q5106
NDCDrug nameLabelerPackage sizeBilling units / package
00069-1305-10RetacritPfizer Inc1 × 1020
00069-1306-10RetacritPfizer Inc1 × 1030
00069-1307-10RetacritPfizer Inc1 × 1040
00069-1308-10RetacritPfizer Inc1 × 10100
00069-1309-04RetacritPfizer Inc1 × 4160
00069-1311-10RetacritPfizer Inc1 × 10200
00069-1318-10RetacritPfizer Inc2 × 10100
59353-0002-10RetacritVifor (International) Inc.1 × 1020
59353-0003-10RetacritVifor (International) Inc.1 × 1030
59353-0004-10RetacritVifor (International) Inc.1 × 1040
59353-0120-10RetacritVifor (International) Inc.1 × 10200
59353-0220-10RetacritVifor (International) Inc.2 × 10100

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for Q5106. For practitioners the limit is 60 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for Q5106 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services603 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital603 Date of Service Edit: ClinicalPrescribing Information

MUE for Q5106 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q5106 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q5106 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q5106 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

4 current Medicare Administrative Contractor articles list Q5106 in their HCPCS tables, covering 15 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing Q5106
ArticleTitleContractor(s)StatesRelated LCD
A56462Billing and Coding: Erythropoiesis Stimulating Agents (ESA)CGS Administrators, LLCKY OHL34356
A56795Billing and Coding: Erythropoiesis Stimulating Agents (ESAs)Wisconsin Physicians Service Insurance CorporationIA KS MO NEL34633, L38446
A58982Billing and Coding: Erythropoiesis Stimulating AgentsPalmetto GBANC SC VA WVL39237
A60381Billing and Coding: Erythropoiesis Stimulating AgentsWellpoint FederalCT IL MN NY WIL40334

Diagnoses Medicare contractors cover for Q5106

4 billing and coding articles attach a covered diagnosis list to Q5106: 1,489 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for Q5106
ICD-10-CMDescription (FY2027)Articles covering
D63.1Anemia in chronic kidney disease4 of 4
I12.0Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease4 of 4
I13.11Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease4 of 4
I13.2Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease4 of 4
N18.32Chronic kidney disease, stage 3b4 of 4
N18.4Chronic kidney disease, stage 4 (severe)4 of 4
N18.5Chronic kidney disease, stage 54 of 4
B20Human immunodeficiency virus [HIV] disease4 of 4
B97.35Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere4 of 4
D61.1Drug-induced aplastic anemia4 of 4
D47.1Chronic myeloproliferative disease4 of 4
D46.0Refractory anemia without ring sideroblasts, so stated4 of 4
D46.1Refractory anemia with ring sideroblasts4 of 4
D46.20Refractory anemia with excess of blasts, unspecified4 of 4
D46.21Refractory anemia with excess of blasts 14 of 4
1,474 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to Q5106 are counted here: a group whose instructions name Q5106, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to Q5106, by article
ArticleContractorGroups that applyCovered codes for Q5106Full list
A56462CGS Administrators, LLCone list for every code in the article1,253On LCD L34356
A56795Wisconsin Physicians Service Insurance Corporation10 groups apply to Q5106325On LCD L34633
A58982Palmetto GBA5 groups apply to Q51061,080On LCD L39237
A60381Wellpoint Federal6 groups apply to Q51061,290On LCD L40334

Local coverage policies that list Q5106

4 active Local Coverage Determinations list Q5106 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

  • Erythropoiesis Stimulating Agents (L39237) · Palmetto GBA
  • L34356 Erythropoiesis Stimulating Agents (ESA) · CGS Administrators, LLC
  • L34633 Erythropoiesis Stimulating Agents (ESAs) · Wisconsin Physicians Service Insurance Corporation
  • L40334 Erythropoiesis Stimulating Agents · Wellpoint Federal

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q5106 carries status indicator K and is assigned to APC 9097, with a published national unadjusted payment of $8.171. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q5106 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $8.17 per 1000 UNITS, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q5106 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q5106

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q5106

What does HCPCS code Q5106 describe?

Q5106 is defined by CMS as "Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units". Each billing unit represents 1000 UNITS, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q5106 a CPT code?

No. Q5106 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as epoetin alfa-epbx (Retacrit); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5106 reports the drug itself in 1,000 units units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q5106 in October 2026?

The ASP-based payment limit is $8.171 per 1000 UNITS, with 20% beneficiary coinsurance. The July 2026 limit was $7.968. Commercial payers use their own fee schedules.

How many units of Q5106 can be billed per day?

The practitioner Medically Unlikely Edit is 60 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to Q5106?

The October 2026 ASP crosswalk lists 12 NDCs from 2 labelers: Retacrit (Pfizer Inc); Retacrit (Vifor (International) Inc.). For example NDC 00069-1305-10 (package size 1) equals 20 billing units of Q5106.

Does Q5106 have NCCI bundling edits?

No active practitioner PTP pairs list Q5106 as a column-1 or column-2 code in the v323r0 release.

Q5106 vs Q5105: what is the difference?

Both are HCPCS Level II codes whose descriptor names epoetin alfa-epbx. What sets Q5105 apart: for ESRD patients on dialysis; billed per 100 units. Q5106 is billed per 1000 units, limit $8.171, MUE 60; Q5105 is billed per 100 units, limit $0.817, MUE 100. Report the code whose descriptor matches the product and setting in the record.

Q5106 vs Q4081: what is the difference?

Both are HCPCS Level II codes whose descriptor names epoetin alfa. What sets Q4081 apart: for ESRD patients on dialysis; non-biosimilar epoetin alfa; billed per 100 units. Q5106 is billed per 1000 units, limit $8.171, MUE 60; Q4081 is billed per 100 units, limit $0.667, MUE 100. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention Q5106?

4 current Billing and Coding Articles in the Medicare Coverage Database list Q5106, covering 15 states: A56462 (Billing and Coding: Erythropoiesis Stimulating Agents (ESA)); A56795 (Billing and Coding: Erythropoiesis Stimulating Agents (ESAs)); A58982 (Billing and Coding: Erythropoiesis Stimulating Agents).

What diagnosis codes support Q5106?

4 Medicare billing and coding articles list 1,489 covered ICD-10-CM codes for Q5106 between them, for example D63.1 (Anemia in chronic kidney disease); I12.0 (Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease); I13.11 (Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease); I13.2 (Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease); N18.32 (Chronic kidney disease, stage 3b). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.